Funktion und klinische Bedeutung des Plasminogen-Aktivator-Inhibitors PAI-1 bei gynäkologischen Malignomen. Eine Übersicht

D. Könsgen; A. Mustea; W. Lichtenegger; J. Sehouli

doi:10.1055/s-2005-836407

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000105.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Zentralbl Gynakol 2005; 127(3): 125-131
DOI: 10.1055/s-2005-836407

Übersicht

Funktion und klinische Bedeutung des Plasminogen-Aktivator-Inhibitors PAI-1 bei gynäkologischen Malignomen. Eine Übersicht[*]

Role of PAI-1 in Gynaecological MalignanciesD. Könsgen¹ , A. Mustea¹ , W. Lichtenegger¹ , J. Sehouli¹

¹Klinik für Frauenheilkunde und Geburtshilfe, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin

Further Information

Publication History

Publication Date:
25 May 2005 (online)

Abstract
Full Text
References

Buy Article Permissions and Reprints

Zusammenfasssung

Der sog. Plasminogen-Aktivator-Inhibitor PAI-1 steht in den letzten Jahren zunehmend im Fokus der gynäkologischen Onkologie. Der vorliegende Beitrag beleuchtet zum einen die physiologischen und pathophysiologischen Zusammenhänge und diskutiert zum anderen den prognostischen Stellenwert des PAI-1 bei verschiedenen gynäkologischen Malignomen.

Abstract

The plasminogen activator-plasmin cascade plays a central role in tumor cell invasion and metastasis of solid tumors. The type-1 plasminogen activator inhibitor (PAI-1) is the major physiologic regulator of the plasminogen activation. The PAI-1 is suggested to play a crucial role in tumor cell invasion and metastasis of different solid tumors. The aim of this article is to give an overview of the function, clinical and prognostic role of PAI-1 in gynaecological malignancies.

Schlüsselwörter

PAI-I - Ovarialkarzinom - gynäkologische Malignome

Key words

PAI-1 - ovarian cancer - gynaecological malignancies

1 Auszüge aus dem Manuskript wurden auf dem „1. Berliner Symposium: Molekularbiologie in der Gynäkologischen Onkologie - Quo vadis 2004” präsentiert

Literatur

1 Andreasen P A, Georg B, Lund L R, Riccio A, Stacey S N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol cell Endocrinol. 1990; 68 1-19

Crossref PubMed Search in Google Scholar
2 Andreasen P A, Kjoller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72 1-22

Crossref PubMed Search in Google Scholar
3 Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature. 1976; 261 595-597

PubMed Search in Google Scholar
4 Berger D H. Plasmin/Plasminogen System in Colorectal Cancer. World J Surg. 2002; 26 767-771

Crossref PubMed Search in Google Scholar
5 Bouchet C, Hacene K, Martin P M, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol. 1999; 17 3048-3057

PubMed Search in Google Scholar
6 Cantero D, Friess H, Deflorin J. et al . Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Thromb Haemost. 1997; 77 62-70

PubMed Search in Google Scholar
7 Chambers S K, Ivins C M, Carangiu M L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer. 1998; 79 449-454

Crossref PubMed Search in Google Scholar
8 Choong P FM, Anne P W. Urokinase Plasminogen activatot System. A multifunctional role in tumor progression and metastasis. Clin Orthop Rel Res. 2003; 415 (Suppl) 46-58

PubMed Search in Google Scholar
9 Cubellis M V, Wun T C, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by ist specific inhibitor PAI-1. EMBO J. 1990; 9 1079-1085

PubMed Search in Google Scholar
10 Danri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A, Del Toro-Arreola S, Bravo-Cuellar A, Perez-Montfort R, Orbach-Arbouys S. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur J Cancer. 1998; 34 566-569

Crossref PubMed Search in Google Scholar
11 De Bruin P A, Griffioen G, Verspaget H W. et al . Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res. 1988; 48 4520-4524

PubMed Search in Google Scholar
12 Deng G, Royle G, Seiffert D, Loskutoff D J. The PAI-1/vitronectin interaction: two cats in a bag?. Thrombosis Haemostasis. 1995; 74 66-70

PubMed Search in Google Scholar
13 Donate L E, Gherardi E, Srinivasav N, Sowdhamini R, Aparicio S, Blundell T L. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci. 1994; 3 2378-2394

PubMed Search in Google Scholar
14 Duffy M J, O'Grady P, Devaney D, O'Siorain L, Fennelly J J, Lijnen H J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988; 62 531-533

PubMed Search in Google Scholar
15 Duval-Jobe C, Parmely M J. Regulation of plasminogen activation by human U937 promoocytic cells. J biol Chem. 1994; 269 21 353-21 357

PubMed Search in Google Scholar
16 Eppenberger U, Kueng W, Schlaeppi J M, Roesel J L, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens J A, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol. 1998; 16 3129-3136

PubMed Search in Google Scholar
17 Ferno M, Bendahl P O, Borg A, Brundell J, Hirschberg L, Olsson H, Killander D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Europ J Cancer. 1996; 32 793-801

Crossref PubMed Search in Google Scholar
18 Foekens J A, Peters H A, Look M P, Portengen H, Schmitt M, Kramer M D, Brunner N, Janicke F, Meijer-van Gelder M E, Henzen-Logmans S C, Putten W L, van Klijn J G. The urokinase system of plasminogen activation and prognosis in 2 780 breast cancer patients. Cancer Res. 2000; 60 636-643

PubMed Search in Google Scholar
19 Foekens J A, Schmitt M, van Putten W L, Peters H A, Kramer M D, Janicke F, Klijn J G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 1994; 12 1648-1658

PubMed Search in Google Scholar
20 Fredstorp-Lidebring M, Bendahl P O, Brunner N, Casslen B, Hogberg T, Langstrom-Einarsson E, Willen R, Ferno M. Urokinase plasminogen activator and ist inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer. 2001; 37 2339-2348

Crossref PubMed Search in Google Scholar
21 Fujimoto J, Hori M, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Comparative study on expression of plasminogen activator inhibitor 1 and its mRNA in endometrial cancers and normal endometria. Tumour Biol. 1997; 18 13-21

PubMed Search in Google Scholar
22 Ginsburg D, Zeheb R, Yang A Y, Rafferty U M, Andreasen P A, Nielsen L, Dano K, Lebo R V, Gelehrter T D. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest. 1986; 78 1673-1680

Crossref PubMed Search in Google Scholar
23 Gleeson N C, Gonsalves R, Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer. 1993; 72 1670-1672

Crossref PubMed Search in Google Scholar
24 Grondahl-Hansen J, Christensen I J, Rosenquist C, Brunner N, Mouridsen H T, Dano K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993; 53 2513-2521

PubMed Search in Google Scholar
25 Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyl E, Reuning U. Integrin αvβ/Vitronectin Interaction affects expression of the urokinase System in human ovarian cancer cells. J Biol Chem. 2001; 276 26 340-26 348

PubMed Search in Google Scholar
26 Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsins D and L in primary breast cancer. Int J Biol Markers. 2000; 15 79-83

PubMed Search in Google Scholar
27 Harbeck N, Kates R E, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol. 2002; 20 1000-1007

PubMed Search in Google Scholar
28 Harbeck N, Schmitt M, Kate R E, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1. Determination in primary breast cancer tissue for individualized therapy concepts. Clinical Breast Cancer. 2002; 3 196-200

PubMed Search in Google Scholar
29 Hazelbag S, Kenter G G, Gorter A, Fleuren G J. Prognostic relevance of TGF-beta 1 and PAI-1 in cervical cancer. Int J Cancer. 2004; 112 1020-1028

Crossref PubMed Search in Google Scholar
30 Herszenyi L, Plebani M, Carraro P. et al . The role of cysteine and serine proteases in colorectal carcinoma. Cancer. 1999; 86 1135-1142

Crossref PubMed Search in Google Scholar
31 Hoffmann G, Casper F, Weikel W, Kummerl T, Pollow B, Schaffrat M, Hoffmann M, Pollow K. Value of p53, urokinase plaminogen activator, PAI-1 and Ki-67 in vulvar carcinoma. Zentralbl Gynakol. 1999; 121 473-478

PubMed Search in Google Scholar
32 Hoffmann G, Pollow K, Weikel W, Strittmatter H J, Bach J, Schaffrath M, Knapstein P, Melchert F, Pollow B. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin Chem Lab Med. 1999; 37 47-54

Crossref PubMed Search in Google Scholar
33 Horn L C, Pippig S, Raptis G, Fischer U, Kohler U, Hentschel B, Martin R. Clinical relevance of urokinase-type plasminogen activator and ist inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix. Aust N Z J Obstet Gynaecol. 2002; 42 383-386

PubMed Search in Google Scholar
34 Jänicke F, Prechtl A, Thommsen C. et al . Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type-1. J Natl Cancer Inst. 2001; 93 913-920

Crossref PubMed Search in Google Scholar
35 Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase plasminogen activator (u-PA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993; 24 195-208

PubMed Search in Google Scholar
36 Kim S J, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res. 1998; 4 177-182

PubMed Search in Google Scholar
37 Klinger K W, Winqvist R, Riccio A, Andreasen P A, Sartorio R, Nielsen L S, Stuart N, Stanislovitis P, Watkins P, Douglas R, Grzeschik K H, Alitalo K, Blasi F, Dano K. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA. 1987; 84 8548-8552

PubMed Search in Google Scholar
38 Knoop A, Andreasen P A, Andersen J A, Hansen S, Laenkholm A V, Simonsen A C, Andersen J, Overgaard J, Rose C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer. 1998; 77 932-940

Crossref PubMed Search in Google Scholar
39 Kobayasi H, Fujishiro S, Terao T. Impact of urokinase type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994; 54 6539-6548

PubMed Search in Google Scholar
40 Köhler U, Hiller R, Martin D. et al . Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma. Gynecol Oncol. 1997; 66 268-274

Crossref PubMed Search in Google Scholar
41 Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clinical Cancer Research. 2001; 7 1743-1749

PubMed Search in Google Scholar
42 Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Urokinase (u-PA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol. 1994; 55 401-409

Crossref PubMed Search in Google Scholar
43 Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Janicke F, Schmitt M, Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer. 1999; 79 1746-1751

Crossref PubMed Search in Google Scholar
44 Kute T E, Grondahl-Hansen J, Shao S M, Long R, Russell G, Brunner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat. 1998; 47 9-16

PubMed Search in Google Scholar
45 Lauffenburger D. Making connections count. Nature. 1996; 383 390-391

Crossref PubMed Search in Google Scholar
46 Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991; 64 327-336

Crossref PubMed Search in Google Scholar
47 Liu G, Shuman M A, Cohen R L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 1995; 60 501-506

PubMed Search in Google Scholar
48 Look M P, van Putten W LJ, Duffy M J. et al . Pooled analysis of prognostic impact of u-PA and PAI-1 in 8 377 breast cancer patients. J Natl Cancer Inst. 2002; 94 116-128

Crossref PubMed Search in Google Scholar
49 Murphy G, Stanton H, Cowell S. et al . Mechanisms for pro matrix metalloproteinases activation. APMIS. 1999; 107 38-44

PubMed Search in Google Scholar
50 Naldini L, Vigna E, Bardelli A. et al . Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by stoichiometric reaction. J Biol Chem. 1995; 270 603-611

Crossref PubMed Search in Google Scholar
51 Nekarda H, Siewert J, Schmitt M and Ulm K. Tumor-associated proteolytic factors u-PA and PAI-1 and survival in totally resected gastric cancer. Lancet. 1994; 343 117

Crossref PubMed Search in Google Scholar
52 Nykjaer A, Conese M, Christensen E I, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of uPA: Serpin complexes. EMBO J. 1997; 16 2610-2620

Crossref PubMed Search in Google Scholar
53 Oka T, Ishida T, Nishino T, Sugimachi K. Immunhistochemical evidence for urokinase plasminogen activator in primary and metastatic tumors of pulmonary carcinoma. Cancer Res. 1991; 51 3522-3525

PubMed Search in Google Scholar
54 Park J E, Keller G A, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993; 4 1317-1326

Crossref PubMed Search in Google Scholar
55 Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen H H, Dano K, Brünner N. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma. Cancer Res. 1994; 54 120-123

PubMed Search in Google Scholar
56 Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof E KO, Lijnen H R, Burtin P. The plasminogen-activation system in ovarian tumors. Int J Cancer. 1993; 55 27-31

PubMed Search in Google Scholar
57 Riethdorf L, Riethdorf S, Petersen S, Bauer M, Herbst H, Janicke F, Loning T. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. J Pathol. 1999; 189 245-250

PubMed Search in Google Scholar
58 Saito K, Nagashima M, Itawa M. et al . The concentration of tissue plasminogen activator and urokinase in plasma and tissue of patients with ovarian and uterine tumors. Thromb Res. 1990; 58 355-366

Crossref PubMed Search in Google Scholar
59 Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 1995; 55 3958-3963

PubMed Search in Google Scholar
60 Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridmann R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001; 7 2396-2404

PubMed Search in Google Scholar
61 Schmitt M, Harbeck N, Thomsson C. et al . Clinical impact of plasminogen activation system in tumour invasion and metastasis: Prognostic relevance and target for therapy. Thromb Haemost. 1997; 78 285-296

PubMed Search in Google Scholar
62 Sheng S. The urokinase-type plaminogen activator system in prostate cancer metastasis. Cancer and Metastasis Reviews. 2001; 20 287-296

Crossref PubMed Search in Google Scholar
63 Skelly M M, Troy A, Duffy M J. et al . Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res. 1997; 3 1837-1840

PubMed Search in Google Scholar
64 Stefansson S, Lawrence D A. The serpin PAI-1 inhibits cell migration by blocking intergrin αvβ3 binding to vitronectin. Nature. 1996; 383 441-443

Crossref PubMed Search in Google Scholar
65 Sweep C G, Geurts-Moespot J, Grebenschikov N, de Witte J H, Heuvel J J, Schmitt M, Duffy M J, Janicke F, Kramer M D, Foekens J A, Brunner N, Brugal G, Pedersen A N, Benraad T J. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer. 1998; 78 1434-1441

PubMed Search in Google Scholar
66 Taponeco F, Curcio C, Giuntini A, Nardini V, Fornaciari G, Artini P G, D'Ambrogio G, Genazzani A R. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer. J Exp Clin Cancer Res. 2001; 20 239-246

PubMed Search in Google Scholar
67 Tecimer C, Doering D L, Goldsmith L J, Meyer J S, Abdulhay G, Wittliff J L. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer. 2000; 10 372-381

Crossref PubMed Search in Google Scholar
68 Tecimer C, Doering D L, Goldsmith L J, Meyer J S, Abdulhay G, Wittliff J L. Clinical relevance of urokinase-type plasminogen activator, its receptor, its inhibitor type 1 in endometrial cancer. Gynecol Oncol. 2000; 80 48-55

PubMed Search in Google Scholar
69 Van der Burg M EL, Henzen-Logmans S C, Berns E MJJ, Putten W LJ, van Klijn J GM, Foekens J A. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer (Pred Oncol). 1996; 69 475-479

Crossref PubMed Search in Google Scholar
70 Vassalli J D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985; 100 86-92

Crossref PubMed Search in Google Scholar
71 Wang S N, Miyauchi M, Koshikawa N. et al . Antigen expression associated with lymph node metastasis in gastric adenocarcinomas. Pathol Int. 1994; 44 844-849

PubMed Search in Google Scholar

1 Auszüge aus dem Manuskript wurden auf dem „1. Berliner Symposium: Molekularbiologie in der Gynäkologischen Onkologie - Quo vadis 2004” präsentiert

D. Könsgen

Klinik für Frauenheilkunde und Geburtshilfe · Campus Virchow-Klinikum · Charité Universitätsmedizin

10117 Berlin

Phone: 0 30/4 50 56 40 52

Fax: 0 30/4 50 56 49 52